89Bio Inc.

10/15/2024 | Press release | Distributed by Public on 10/15/2024 06:55

89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.